Rituximab for children with symptoms corresponding to the research condition of PANS/PANDAS with respect to health-related quality of life, level of functioning, and symptoms

What evidence is needed?

More primary research is needed.

What evidence is available?

Reliable systematic reviews that show evidence gaps:

Johnson M, Ehlers S, Fernell E, Hajjari P, Svanberg T, Svensson, M, Vikberg Adania U, Wartenberg C, Wallerstedt SM. Anti-inflammatory, antibiotic and immunomodulatory treatment in children with symptoms corresponding to the research condition PANS (Pediatric Acute-onset Neuropsychiatric Syndrome) [Behandling mot en förmodad hjärninflammation utan påvisad neurologisk eller medicinsk sjukdom hos barn med plötsligt debuterande tvångssymtom/begränsningar i matintag i kombination med minst två neuropsykiatriska symtom (”PANS”)]. Göteborg: Västra Götalandsregionen, Sahlgrenska Universitetssjukhuset, HTA-centrum; 2020. Regional activity based HTA 2020:115. More about the review

Reliable, but not updated, systematic reviews that show evidence gaps:

None identified

Registration number:
Research conducted after publication could potentially change the nature of the evidence.

Evidence gap identifies methods or practices for which no conclusive systematic review of benefits and harms has been published. Gaps in scientific evidence appear on the SBU website to help researchers and granting agencies identify areas that are in need of research or systematic review. An additional objective is to offer healthcare and social service providers a basis for setting priorities.